共 132 条
[1]
Boyle P(2005)Cancer incidence and mortality in europe, 2004 Ann Oncol 16 481-8
[2]
Ferlay J(2008)Cancer statistics, 2008 CA: Cancer J Clinic 58 71-96
[3]
Jemal A(2014)Cancer statistics, 2014 Ca-a Cancer J Clinic 64 9-29
[4]
Siegel R(1999)Eligibility and response guidelines for phase ii clinical trials in androgen-independent prostate cancer: recommendations from the prostate-specific antigen working group J Clin Oncol 17 3461-7
[5]
Ward E(2009)Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer J Urol 181 2520-5
[6]
Hao Y(2002)Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer J Urol 168 995-1000
[7]
Xu J(2004)Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer Int J Cancer 108 877-81
[8]
Murray T(2006)Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (int-0162) J Clinical Oncol 24 3984-90
[9]
Thun MJ(2007)Time to an undetectable prostate-specific antigen (psa) after androgen suppression therapy for postoperative or postradiation psa recurrence and prostate cancer-specific mortality Cancer 109 1290-5
[10]
Siegel R(2009)Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy Cancer 115 981-7